
Dynavax Technologies Corporation DVAX
Dynavax Technologies Corporation Cash Conversion Cycle | DVAX
Annual Cash Conversion Cycle Dynavax Technologies Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 459 | 525 | 146 | 183 | 1.6 K | 696 | 395 | - | - | - | - | - | - | - | 7.63 | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.6 K | 7.63 | 502 |
Quarterly Cash Conversion Cycle Dynavax Technologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 520 | 525 | 501 | - | 471 | 512 | 523 | - | 390 | 448 | 571 | - | 74.1 | 32.2 | 134 | - | 234 | 164 | 292 | - | 196 | 775 | 132 | 76.7 | 76.7 | 97.7 | 99.5 | 63.6 | 231 | 270 | 1.26 K | 3.71 K | 1.47 K | 742 | 677 | 16.8 | 756 | 43.2 | 124 | 170 | 69.9 | 46.1 | 119 | 29.1 | 30 | 21.8 | 30.7 | 52.1 | 50.7 | 43.8 | 57.6 | 50.8 | 31.9 | 34.2 | 204 | 76.1 | 740 | 120 | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.71 K | 16.8 | 343 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Brickell Biotech
BBI
|
26 | - | -5.38 % | $ 6.06 M | ||
|
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-4.37 K | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
18.6 | - | - | $ 5.78 B | ||
|
AbbVie
ABBV
|
284 | $ 291.22 | 1.06 % | $ 515 B | ||
|
22nd Century Group
XXII
|
108 | $ 1.56 | -19.17 % | $ 287 K | ||
|
Axon Enterprise
AXON
|
64.5 | $ 313.68 | -18.01 % | $ 24.5 B | ||
|
Biogen
BIIB
|
337 | $ 248.51 | 1.88 % | $ 36.4 B | ||
|
Theratechnologies
THTX
|
178 | - | - | $ 83.9 M | ||
|
Exelixis
EXEL
|
-8.32 | $ 69.55 | 1.22 % | $ 18.9 B | ||
|
Gilead Sciences
GILD
|
115 | $ 166.9 | -0.4 % | $ 208 B | ||
|
Grifols, S.A.
GRFS
|
0.000171 | $ 8.46 | -0.12 % | $ 5.75 B | ||
|
Alnylam Pharmaceuticals
ALNY
|
31.7 | $ 155.97 | -0.44 % | $ 20.4 B | ||
|
Insmed Incorporated
INSM
|
173 | $ 114.55 | 5.32 % | $ 22.8 B | ||
|
Johnson & Johnson
JNJ
|
88.2 | $ 274.89 | 0.95 % | $ 662 B | ||
|
Titan Pharmaceuticals
TTNP
|
81.3 | - | -3.76 % | $ 3.47 M | ||
|
Lineage Cell Therapeutics
LCTX
|
19.2 | $ 1.02 | 3.75 % | $ 235 M | ||
|
Longeveron
LGVN
|
-212 | $ 1.82 | 6.43 % | $ 32 B | ||
|
Crinetics Pharmaceuticals
CRNX
|
-4.27 K | $ 84.95 | 0.13 % | $ 7.99 B | ||
|
Mesoblast Limited
MESO
|
0.01 | $ 14.26 | 1.13 % | $ 17.2 B | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-24.8 K | - | -15.15 % | $ 60.3 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-284 | - | - | $ 521 M | ||
|
Codexis
CDXS
|
-15.2 | $ 1.09 | 6.37 % | $ 95 M | ||
|
MannKind Corporation
MNKD
|
349 | $ 3.91 | 4.0 % | $ 1.2 B | ||
|
Merck & Co.
MRK
|
110 | $ 146.81 | -0.07 % | $ 367 B | ||
|
Curis
CRIS
|
64.7 | $ 0.88 | 3.67 % | $ 11.6 M | ||
|
Cyclerion Therapeutics
CYCN
|
137 | $ 34.99 | 3.77 % | $ 147 M | ||
|
Завод ДИОД
DIOD
|
-32.7 | - | - | - | ||
|
CorMedix
CRMD
|
359 | $ 5.31 | 1.43 % | $ 383 K | ||
|
Novartis AG
NVS
|
0.04 | $ 162.64 | 0.44 % | $ 315 B |